Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 9/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 2/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.46 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466099 | 0.87 | FGFR2 (0.78) | FGFR2KDRMETPDGFRA | |
| SCHEMBL1703677 | 0.82 | KIT (0.48) | FGFR2KDRPDGFRAKCNH2SCN5A | |
| SCHEMBL16389038 | 0.81 | FGFR2 (0.53) | FGFR2KDREGFRGAKRIPK2 | |
| SCHEMBL20460397 | 0.77 | RUNX1 (0.54) | FGFR2GAKRIPK2COQ8ANLK | |
| SCHEMBL21611894 | 0.76 | TNF (0.67) | EGFRRIPK2KCNH2SCN5ASCN9A | |
| SCHEMBL7653871 | 0.76 | EGFR (0.77) | KDREGFRGAKRIPK2 | |
| SCHEMBL30420525 | 0.75 | HTT (0.70) | FGFR2EGFRGAKRIPK2COQ8A | |
| Hydrochloric Acid SCHEMBL23607655 | 0.75 | TNF (0.66) | EGFRRIPK2 | |
| SCHEMBL30012803 | 0.75 | ABL1 (0.47) | KCNH2SCN5ASCN9A | |
| SCHEMBL23611049 | 0.75 | ABL1 (0.47) | KCNH2SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-3016656-B1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2021-09-08 | — | — | EP | claimed |
| EP-3521283-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-08-07 | — | — | EP | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-9637475-B2 | Compounds for treating cancer | ABIVAX (FR) | 2017-05-02 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-22 | — | — | US | claimed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| EP-2440545-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2024-10-17 | — | — | US | disclosed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | FGFR2 4068/4885KDR 4012/4885EGFR 4135/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | FGFR2 1736/4885KDR 3134/4885EGFR 1693/4885 |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | FGFR2 2778/4885KDR 4469/4885EGFR 2069/4885 |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | FGFR2 485/4885KDR 1958/4885EGFR 226/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | FGFR2 3336/4885KDR 4279/4885EGFR 4475/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | FGFR2 3143/4885KDR 3700/4885EGFR 3492/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | FGFR2 620/4885KDR 1856/4885EGFR 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.